.jpg)
Aravax Appoints Dr Adrian Parry as Director of CMC as it Continues to Build Phase 3 Development Capabilities
Melbourne, Australia and Oxford, UK– 23 June 2025, a clinical-stage biotechnology company developing next-generation, disease-modifying...
Jun 23
Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development
Melbourne, Australia and Oxford, UK– 2 June 2025, Aravax, a clinical-stage biotechnology company developing next-generation,...
Jun 2
Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer
Melbourne, Australia and Oxford, UK– 21 January 2025 , Aravax, a clinical-stage biotechnology company developing precisely targeted...
Jan 21
Aravax Establishes Pharmaceutical Development base on the Oxford Science Park with a Focus on Developing Manufacturing Capabilities in the UK
Melbourne, Australia and Oxford, UK– 14 November 2024, Aravax, a clinical-stage biotechnology company developing next-generation...
Nov 14, 2024
Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy
Melbourne, Australia – 28 October 2024: Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies...
Oct 28, 2024
Aravax Appoints Dr Paul Laidler as VP Pharmaceutical Development
1 May 2024, Melbourne, Australia: Aravax, a clinical-stage biotechnology company developing next- generation immunotherapies which are...
May 1, 2024